title: Septic shock caused by Plesiomonas shigelloides in a patient with sickle beta-zero thalassemia.
abstract: Invasive infection and extraintestinal complications are rarely caused by Plesiomonas shigelloides, a waterborne bacterium belonging to the Vibrionaceae family. We report a case of a 16-year-old female patient with sickle beta-zero thalassemia who survived septic shock caused by P. shigelloides associated with secondary acute respiratory distress syndrome and disseminated intravascular coagulation. Treatment with a carbapenem was successful, and the patient recovered without any sequelae. The previous reports of P. shigelloides sepsis are cited, and possible pathogenic mechanisms are discussed.
authors.affiliation: Centro de Terapia Intensiva (Campus), Departamento de Cirurgia e Anatomia, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, HCFMRP-USP, Ribeirão Preto, SP, Brasil. mamartins@hcrp.usp.br <mamartins@hcrp.usp.br>
authors.forename: Maria
authors.initials: M
authors.lastname: Auxiliadora-Martins
authors.forename: Fernando
authors.initials: F
authors.lastname: Bellissimo-Rodrigues
authors.forename: Jaciara Machado
authors.initials: JM
authors.lastname: Viana
authors.forename: Gil Cezar Alkmin
authors.initials: GC
authors.lastname: Teixeira
authors.forename: Edson Antônio
authors.initials: EA
authors.lastname: Nicolini
authors.forename: Kátia Simone Muniz
authors.initials: KS
authors.lastname: Cordeiro
authors.forename: Giovana
authors.initials: G
authors.lastname: Colozza
authors.forename: Roberto
authors.initials: R
authors.lastname: Martinez
authors.forename: Olindo Assis
authors.initials: OA
authors.lastname: Martins-Filho
authors.forename: Anibal
authors.initials: A
authors.lastname: Basile-Filho
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D015780:Carbapenems / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D016638:Critical Illness; D004211:Disseminated Intravascular Coagulation; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D006451:Hemoglobin, Sickle / Q000032:analysis*; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D007362:Intensive Care Units; D008795:Metronidazole / Q000627:therapeutic use; D016981:Plesiomonas / Q000302:isolation & purification*; D012128:Respiratory Distress Syndrome; D012772:Shock, Septic / Q000188:drug therapy* / Q000382:microbiology; D013789:Thalassemia / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D015780:Carbapenems; D006451:Hemoglobin, Sickle; D008795:Metronidazole; D015378:Imipenem; D002443:Ceftriaxone; D017291:Clarithromycin